Two people embracing.
Actor portrayal.

Welcome to PURPOSE 2

Even though a variety of prevention options exist, HIV remains a serious health concern for many people around the world.

In the United States, socioeconomic inequity, racism, stigma, homophobia, transphobia, and other factors have led to higher rates of HIV in some communities. PURPOSE 2 will test whether an investigational PrEP (pre-exposure prophylaxis) medicine, lenacapavir, helps reduce the chance of getting HIV through sex.

The study was designed to include groups who are underrepresented in HIV prevention trials and are disproportionately affected by the HIV epidemic.

PURPOSE 2 has completed enrollment and is currently in progress. We look forward to publishing the results of this study soon!

More information about the PURPOSE 2 study can also be found at clinicaltrials.gov.

Person standing at a microphone.
Actor portrayal.

"How Is This Related to Me?"

First, this is an opportunity to advance our knowledge of HIV prevention and help develop more PrEP options.

Second, this is a chance to help change how medical research is done.

Key groups including Black and transgender people have been underrepresented in clinical trials. It’s time to change that. We are committed to fair inclusion of all groups in PURPOSE 2, so that what we learn can benefit all.

Two people talking in bed.
Actor portrayal.

A Global Problem Deserves a Global Effort

PURPOSE 2 is being done in the United States, South Africa, Peru, Brazil, Argentina, Mexico, and Thailand, and includes cisgender men, transgender women, transgender men, and gender non-binary individuals who have sex with partners assigned male at birth.

Our Commitment to Inclusion

From day 1, Gilead designed the PURPOSE 2 study with all people who would benefit from PrEP in mind.

Explore a video from Moupali Das, MD, MPH, the Executive Director of HIV Clinical Development at Gilead, as she describes why it was important that PURPOSE add study sites in new locations in the country.

Global Community Advisors

Explore a video from Moupali Das, MD, MPH, the Executive Director of HIV Clinical Development at Gilead, as she describes why it was important that PURPOSE add study sites in new locations in the country.

Global Community Advisors